From the Department of Respiratory Medicine (Drs José and Lipman) and the Ian Charleson Centre for HIV Medicine (Mr Marshall), Royal Free Hospital.
Correspondence to: Ricardo J. José, MBChB, DA(SA), Department of Respiratory Medicine, Royal Free Hospital, Pond St, London, NW3 2PL, England; e-mail: email@example.com
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Mr Marshall has received honoraria for speaker fees, conference registration, and travel expenses from Janssen, Bristol-Myers Squibb, ViiV Healthcare, Abbott, Gilead Science, and Merck Sharp & Dohme. Drs José and Lipman have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
© 2012 American College of Chest Physicians
We read with interest the article by Wahidi et al1 in CHEST (November 2011). We are concerned that the section on midazolam did not provide up-to-date information on interactions between this drug and highly active antiretroviral therapy (ART) used in HIV-infected individuals.
The study that is quoted in the consensus statement suggests that higher doses of midazolam may be needed in certain HIV-infected populations.2 We believe this reflects the situation in IV-drug users who are HIV-positive (the main HIV study group) and are likely to have acquired a tolerance to benzodiazepines through prolonged use. There is no detail provided on ART usage; therefore, the conclusions should not be extrapolated to all patients with HIV.
The majority of current ART regimens contain either potent cytochrome P450 enzyme 3A4 (CYP3A4) inhibitors, such as the HIV protease inhibitor ritonavir, or enzyme inducers, such as the non-nucleoside reverse transcriptase inhibitors efavirenz or nevirapine. Midazolam is extensively metabolized by CYP3A4 and coadministration with, for example, lopinavir/ritonavir results in a fourfold increase in midazolam bioavailability (area under the curve) after parenteral administration.3 This may result in prolonged sedation and other adverse effects such as arrhythmias.
Diazepam at reduced doses has been used in clinical practice with ritonavir (100 to 200 mg daily), although at higher ritonavir doses, it is contraindicated.4 Alternatively, lorazepam has the least potential for interaction with ART of all the currently available benzodiazepines5 used in bronchoscopy. It may be considered in this scenario (where available) despite its disadvantage of a longer onset of action and duration of sedation. The use of benzodiazepines for other patient groups receiving CYP3A4 inhibitors such as macrolide antibiotics, itraconazole, and the new hepatitis C virus NS3 inhibitors (boceprevir and telaprevir) should also be undertaken with caution.
Conversely, the concomitant administration of CYP3A4 inducers such as efavirenz, or rifamycin antibiotics may lead to therapeutic failure of standard-dose benzodiazepines. Dose escalation should be performed with careful clinical and physiologic monitoring.
The response to sedation in patients who are HIV-positive is unpredictable. The choice of sedative and its dosage must be tailored to the individual’s history and most importantly his or her concurrent medication. Increased postprocedure monitoring is mandatory.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.